Get the Stockscreener App
63.15
7.51%
-5.13
After Hours:
62.98
-0.17
-0.27%
Moderna Inc stock is traded at $63.15, with a volume of 5.58M.
It is down -7.51% in the last 24 hours and up +13.99% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$68.28
Open:
$67.07
24h Volume:
5.58M
Relative Volume:
0.75
Market Cap:
$25.06B
Revenue:
$2.23B
Net Income/Loss:
$-3.19B
P/E Ratio:
-7.7521
EPS:
-8.1462
Net Cash Flow:
$-1.60B
1W Performance:
-17.52%
1M Performance:
+13.99%
6M Performance:
+50.97%
1Y Performance:
+96.97%
1-Day Range:
$62.80
$67.42
1-Week Range:
$62.80
$76.72
52-Week Range:
$22.28
$85.60
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
63.15 | 27.09B | 2.23B | -3.19B | -1.60B | -8.1462 |
VRTX
Vertex Pharmaceuticals Inc
|
486.03 | 121.09B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
678.94 | 69.66B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
857.97 | 53.99B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
179.18 | 39.21B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
283.15 | 37.27B | 4.29B | 577.22M | 641.34M | 4.2086 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Resumed | Barclays | Equal Weight |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-12-25 | Initiated | Jefferies | Hold |
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Fed. Circ. Asked Not To Shift Moderna Vax Patent Case To Gov't - Law360
Moderna, Inc.’s Stock Price Plummets to $63.15, Marking a Significant 7.51% Decline - Smartkarma
Moderna president Stephen Hoge sells $3.6m in stock - Investing.com
Form 4 Moderna Inc For: 16 July By Investing.com - Investing.com Canada
Moderna, Inc. (MRNA) president exercises options and sells 53,336 shares under 10b5-1 plan - Stock Titan
Lobbying Update: $290,000 of MODERNA INC. lobbying was just disclosed - Quiver Quantitative
ABUS Stock On Track For Best Day In About Two Months — What’s The Moderna Connection? - Stocktwits
The mRESVAI trial for RSV vaccine by Moderna Inc.early data underline a strategic bet on respirat - ad-hoc-news.de
Moderna advances its cancer therapy assessment, but the stock slides - marketscreener.com
Moderna Announces First Participant Dosed in Phase 1 Clinical Trial Evaluating Investigational Tumor-Targeted Cancer Antigen Therapy in Solid Tumors - Investing News Network
(MRNA) Risk Channels and Responsive Allocation - Stock Traders Daily
Arbutus Files More Patent Infringement Suits Against Pfizer, BioNTech -- Update - marketscreener.com
Moderna (MRNA) Begins Trial for New Cancer Immunotherapy - GuruFocus
Arbutus (ABUS) Secures $178 Million Settlement with Moderna - GuruFocus
Moderna doses first patient in cancer therapy trial - Investing.com
Arbutus Biopharma Files International Patent Lawsuits Against Pfizer and BioNTech, Announces Moderna Settlement Payment and Plans for Capital Return - Quiver Quantitative
Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders - The Manila Times
Arbutus Biopharma (Nasdaq: ABUS) receives $178M from Moderna, eyes $230M buyback - Stock Titan
Moderna Trial Tests Cancer Therapy Encoding Seven Antigens - Stock Titan
Sanofi sues Pfizer, Moderna over COVID shot technology - Reuters
Sanofi Sues Moderna, Pfizer for Vaccine-Tech Patent Royalties - Bloomberg Law News
Form 144 Moderna For: 15 July By Investing.com - Investing.com Canada
Moderna (NASDAQ: MRNA) holder Stephen Hoge plans 53,336-share sale - Stock Titan
Moderna's Ambitious Pivot: Why Its Science Day Vision Outruns Today's Valuation - Kavout | AI
Sanofi Says Pfizer, Moderna COVID Jabs Infringe MRNA Tech - Law360
Gov't Shouldn't Face Vax Suit Targeting Moderna, Group Says - Law360
Moderna set for uneventful Q2 report ahead of key data readouts, says Jefferies - Yahoo Finance
Moderna (MRNA) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance Singapore
Moderna, Takeda and Capricor on the verge of notching big drug approvals - Pharma Voice
The mRESV-101 vaccine candidateModerna Inc. bets on RSV protection in older adults - Ad Hoc News
Jefferies Adjusts Price Target on Moderna to $60 From $53, Maintains Hold Rating - marketscreener.com
What It Means To Hold Moderna Stock In A Crash - Yahoo Finance
Weekly Recap: Moderna names Michael McDonnell to board and $950M patent payout - TradingView
Y Intercept Hong Kong Ltd Sells 444,343 Shares of Moderna, Inc. $MRNA - MarketBeat
Moderna Inc (MRNA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Moderna, Inc. (NASDAQ:MRNA) Receives Average Recommendation of "Reduce" from Brokerages - MarketBeat
Moderna (MRNA) Stock Plunges Over 10% Amid Insider Sales and Bearish Analyst Sentiment - Blockonomi
The mRNA-1273.214 bivalent boosterModerna bets on updated Covid protection - ad-hoc-news.de
Moderna stock holds steady as mRNA pipeline and COVID booster strategy shape long-term outlook - ad-hoc-news.de
Form 4 Moderna Inc For: 10 July By Investing.com - Investing.com Nigeria
Moderna, Inc.’s Stock Price Plummets to $68.27, Witnessing a Sharp 10.83% Decline - Smartkarma
Moderna, Inc. (MRNA) grants RSUs and stock options to director Michael R. McDonnell - Stock Titan
Moderna (MRNA) files Form 3 registering director Michael R. McDonnell as insider - Stock Titan
Moderna (MRNA) Sees Significant Drop in Stock Price - GuruFocus
MRNA Stock Eyes Worst Week In 11 Months After June Surge — What’s Ahead? - Yahoo Finance
Meta, Moderna among market cap stock movers on Friday By Investing.com - Investing.com India
Meta, Moderna among market cap stock movers on Friday - Investing.com
Moderna Stock Sinks 11%; Its 24 Million-Dose EU Deal Has a No-Minimum Catch - TechStock²
Moderna Sees Unusually High Options Volume (NASDAQ:MRNA) - MarketBeat
Biotech Stocks To Keep An Eye OnJuly 10th - MarketBeat
Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout - Yahoo Finance
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.75%
3.94%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):